Skip to main content
Literatur
1.
Zurück zum Zitat Muftuoglu IK, Tsai FF, Gaber R, Alam M, Meshi A, Freeman WR (2017) High-frequency aflibercept injections in persistent neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 255:709–717CrossRefPubMed Muftuoglu IK, Tsai FF, Gaber R, Alam M, Meshi A, Freeman WR (2017) High-frequency aflibercept injections in persistent neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 255:709–717CrossRefPubMed
2.
Zurück zum Zitat Jaffe GJ, Kaiser PK, Thompson D et al (2016) Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid. Ophthalmology 123:1856–1864CrossRefPubMed Jaffe GJ, Kaiser PK, Thompson D et al (2016) Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid. Ophthalmology 123:1856–1864CrossRefPubMed
3.
Zurück zum Zitat Papadopoulos N, Martin J, Ruan Q, Rafique A (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis 15:171–185CrossRefPubMedPubMedCentral Papadopoulos N, Martin J, Ruan Q, Rafique A (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis 15:171–185CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Gharbiya M, Cruciani F, Mariotti C, Grandinetti F, Marenco M, Cacace V (2015) Choroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus aflibercept. J Ocul Pharmacol Ther 31:357–362CrossRefPubMed Gharbiya M, Cruciani F, Mariotti C, Grandinetti F, Marenco M, Cacace V (2015) Choroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus aflibercept. J Ocul Pharmacol Ther 31:357–362CrossRefPubMed
5.
Zurück zum Zitat Julien S, Biesemeier A, Taubitz T, Schraermeyer U (2014) Different effects on intravitreally injected ranibizumab and aflibercept on retinal and chorodial tissues of monkey eyes. Br J Ophthalmol 98:813–825CrossRefPubMed Julien S, Biesemeier A, Taubitz T, Schraermeyer U (2014) Different effects on intravitreally injected ranibizumab and aflibercept on retinal and chorodial tissues of monkey eyes. Br J Ophthalmol 98:813–825CrossRefPubMed
6.
Zurück zum Zitat Călugăru D, Călugăru M (2017) Long-term results of pro re nata regimen of aflibercept treatment in persistent neovascular age-related macular degeneration. Am J Ophthalmol 173:145–146CrossRefPubMed Călugăru D, Călugăru M (2017) Long-term results of pro re nata regimen of aflibercept treatment in persistent neovascular age-related macular degeneration. Am J Ophthalmol 173:145–146CrossRefPubMed
7.
Zurück zum Zitat Călugăru D, Călugăru M (2017) Comparison of time to retreatment and visual function between ranibizumab and aflibercept in age-related macular degeneration. Am J Ophthalmol 174:181–182CrossRefPubMed Călugăru D, Călugăru M (2017) Comparison of time to retreatment and visual function between ranibizumab and aflibercept in age-related macular degeneration. Am J Ophthalmol 174:181–182CrossRefPubMed
8.
Zurück zum Zitat Călugăru D, Călugăru M (2017) Long-term outcomes of aflibercept treatment for neovascular age-related macular degeneration in a clinical setting. Am J Ophthalmol 174:185–186CrossRefPubMed Călugăru D, Călugăru M (2017) Long-term outcomes of aflibercept treatment for neovascular age-related macular degeneration in a clinical setting. Am J Ophthalmol 174:185–186CrossRefPubMed
9.
Zurück zum Zitat Călugăru D, Călugăru M (2017) Aflibercept in persistent neovascular age-related macular degeneration: comparison of different treatment strategies in switching therapy. Eye 31:162CrossRefPubMed Călugăru D, Călugăru M (2017) Aflibercept in persistent neovascular age-related macular degeneration: comparison of different treatment strategies in switching therapy. Eye 31:162CrossRefPubMed
Metadaten
Titel
High-frequency aflibercept injections in persistent neovascular age-related macular degeneration
verfasst von
Dan Călugăru
Mihai Călugăru
Publikationsdatum
08.07.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 10/2017
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-017-3733-7

Weitere Artikel der Ausgabe 10/2017

Graefe's Archive for Clinical and Experimental Ophthalmology 10/2017 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.